Phase 1 Trial of Malaria Transmission Blocking Vaccine Candidates Pfs25 and Pvs25 Formulated with Montanide ISA 51 by Wu, Yimin et al.
Phase 1 Trial of Malaria Transmission Blocking Vaccine
Candidates Pfs25 and Pvs25 Formulated with Montanide
ISA 51
Yimin Wu
1.*, Ruth D. Ellis
1., Donna Shaffer
2, Erica Fontes
2, Elissa M. Malkin
1¤a, Siddhartha Mahanty
1¤b,
Michael P. Fay
3, David Narum
1, Kelly Rausch
1, Aaron P. Miles
1¤c, Joan Aebig
1, Andrew Orcutt
1, Olga
Muratova
1, Guanhong Song
1, Lynn Lambert
1, Daming Zhu
1, Kazutoyo Miura
1, Carole Long
1¤d, Allan
Saul
1¤e, Louis H. Miller
1, Anna P. Durbin
2*
1Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, Rockville, Maryland, United States of America, 2Center for Immunization
Research, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America, 3Biostatistics Research
Branch, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, United States of America
Abstract
Background: Pfs25 and Pvs25, surface proteins of mosquito stage of the malaria parasites P. falciparum and P. vivax,
respectively, are leading candidates for vaccines preventing malaria transmission by mosquitoes. This single blinded, dose
escalating, controlled Phase 1 study assessed the safety and immunogenicity of recombinant Pfs25 and Pvs25 formulated
with Montanide ISA 51, a water-in-oil emulsion.
Methodology/Principal Findings: The trial was conducted at The Johns Hopkins Center for Immunization Research,
Washington DC, USA, between May 16, 2005–April 30, 2007. The trial was designed to enroll 72 healthy male and non-
pregnant female volunteers into 1 group to receive adjuvant control and 6 groups to receive escalating doses of the
vaccines. Due to unexpected reactogenicity, the vaccination was halted and only 36 volunteers were enrolled into 4 groups:
3 groups of 10 volunteers each were immunized with 5 mg of Pfs25/ISA 51, 5 mg of Pvs25/ISA 51, or 20 mg of Pvs25/ISA 51,
respectively. A fourth group of 6 volunteers received adjuvant control (PBS/ISA 51). Frequent local reactogenicity was
observed. Systemic adverse events included two cases of erythema nodosum considered to be probably related to the
combination of the antigen and the adjuvant. Significant antibody responses were detected in volunteers who completed
the lowest scheduled doses of Pfs25/ISA 51. Serum anti-Pfs25 levels correlated with transmission blocking activity.
Conclusion/Significance: It is feasible to induce transmission blocking immunity in humans using the Pfs25/ISA 51 vaccine,
but these vaccines are unexpectedly reactogenic for further development. This is the first report that the formulation is
associated with systemic adverse events including erythema nodosum.
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Introduction
Despite decades of effort, malaria remains a major cause of
morbidity and mortality in humans, causing 300 million clinical
cases and over one million deaths annually [1]. Of the four species of
malaria parasites that infect humans, Plasmodium falciparum is
responsible for the majority of these deaths while P. vivax accounts
for over 50% of all malarial infections outside Africa as well as 10%
of those in Africa. Spreading drug resistance of the malaria parasite
makes chemotherapy increasingly difficult. Alternative strategies to
prevent the infection and disease spread are urgently needed.
Malaria is transmitted by Anopheles mosquitoes. Measures to
block transmission have been integral to malaria control strategies.
Use of insecticide-treated bed nets in endemic regions reduces the
PLoS ONE | www.plosone.org 1 July 2008 | Volume 3 | Issue 7 | e2636number of infectious bites thereby reducing morbidity and
mortality [2]. Malaria transmission blocking vaccines, which
target the sexual development of the parasite in the mosquito
vector, could be another effective means to reduce malaria
transmission. Overall, a sustained reduction in transmission, when
used as a component of a control program, could contribute to
sustained local elimination of the disease.
Pfs25 and Pvs25 proteins expressed on the surface of ookinetes in
the mosquito stage of P. falciparum and P. vivax, respectively, are
leading candidates for malaria transmission blocking vaccines. In
animal studies, these antigens are able to generate strong
transmission blocking activity [3]. In an early human trial volunteers
were primed with NYVAC-Pf7, a viral vector expressing seven P.
falciparumgenesincluding thePfs25gene,followed bya boostingdose
with a recombinant Pfs25 protein [4]. These volunteers developed
some anti-Pfs25 antibodies that had marginal activity in blocking
transmission. The first human vaccine trial targeting P. vivax malaria
transmission tested a recombinant Pvs25 formulated with Alhydro-
gel. Antibodies that developed in some of these volunteers were able
to significantly inhibit parasite development in mosquitoes [5], but
the levels were too low for an effective vaccine.
In order to enhance the immunogenicity of Pfs25 and Pvs25, we
selected Montanide ISA 51 to formulate the vaccines as water-in-oil
emulsions. Montanide ISA 51 has been used as an experimental
adjuvant for protein and peptide vaccines. Like Freund’s Incomplete
Adjuvant (FIA), it is based on mineral oil with a mannide mono-
oleate emulsifier. In contrast to FIA, a highly purified emulsifier is
used in Montanide ISA51, thus avoiding impurities that contributed
to the toxicity of some batches of FIA. It also uses a different ratio of
emulsifier to oil, resulting in a more consistent and controllable
emulsion [6–8]. Experience in human trials indicated that Montanide
ISA 51 was an effective immune enhancer and was generally well
tolerated. Most reported adverse reactions were transient local
reactions, including local swelling and pain with or without fever. In
these studies, mild injection site nodules were reported that resolved
within weeks without medical intervention [9–13].
In this paper we report the results of a Phase 1 trial designed to
evaluate the safety and immunogenicity of the malaria transmis-
sion blocking vaccine candidates Pfs25/ISA 51 and Pvs25/ISA 51
in healthy US adults. This is the first report of erythema nodosum
and leukemoid reactions associated with a combination of an
antigen with the Montanide ISA 51 adjuvant.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Participants
Participants were healthy males and non-pregnant females
between 18 and 50 years old recruited from the metropolitan
Washington DC area. Exclusion criteria included previous receipt
of a malaria vaccine, splenectomy, known immunodeficiency, use
of systemic corticosteroids or immunosuppressive drugs, recent
receipt of a licensed vaccine or blood products, recent or
simultaneous participation in another investigational drug or
vaccine study, abnormal screening laboratories (complete blood
count, aspartate aminotransferase, alanine aminotransferase,
creatinine) or positive urine b-hCG, serologic evidence of hepatitis
B or C infection, antibody to HIV, or any other clinically
significant disease or condition which might confound the
interpretation of study results. A prior history of malaria or recent
travel to a malaria endemic area was not an exclusion criterion.
Ethics
The study was conducted under a protocol reviewed and
approved by the Committee on Human Research (the Johns
Hopkins Bloomberg School of Public Health Institutional Review
Board) and the Institutional Review Board of the National
Institute of Allergy and Infectious Diseases. The study protocol
was submitted to the U.S. Food and Drug Administration for
review as part of Investigational New Drug application BB-IND
#12163. The study was monitored for regulatory compliance and
data quality assurance by the NIAID Regulatory Compliance and
Human Subjects Protection Branch. Written informed consent
was obtained from all volunteers prior to screening for eligibility
for enrollment, in accordance with the Code of Federal
Regulations Title 21, Part 50.
Intervention: Study Agents
Recombinant proteins Pfs25 and Pvs25 were produced in the
yeast expression systems utilizing Pichia pastoris and Saccharomyces
cerevisiae, respectively [14–16]. A hexa-His tag was added to the C-
terminus of the recombinant proteins to facilitate purification and
characterization. Clinical grade Pfs25 and Pvs25 were produced at
the Department of Biologics Research Pilot Bioproduction
Facility, Walter Reed Army Institute of Research (WRAIR, Silver
Spring MD), under current Good Manufacturing Practices
(cGMP) conditions. Each protein was supplied in sterile solution,
and underwent comprehensive quality control analyses to ensure
purity, identity, and integrity.
The vaccines were formulated as previously described with
slight modifications [17]. Briefly, the Pfs25 or Pvs25 at a
concentration of 320 mg/mL in phosphate-buffered saline (PBS,
155 mM NaCl, 1 mMKH2PO4, 3 mM Na2HPO3) was aseptically
emulsified with an equal volume of Montanide ISA 51 to give a
final vaccine concentration of 160 mg/mL. The emulsion was
achieved by homogenizing the mixture in a volume of 200 mL in a
400-mL vessel at room temperature for 6 min at 6000 rpm using
an Omni Mixer-ES homogenizer (Omni International, Warren-
ton, VA). Three lots of clinical grade vaccines were prepared and
vialed by the Pharmaceutical Development Section, The Clinical
Center, National Institutes of Health: Pfs25/ISA 51, 160 mg/mL;
Pvs25/ISA 51, 160 mg/mL; and an adjuvant control vaccine
containing PBS/ISA 51, with volume weighted average droplet
sizes of 0.816 mm, 0.803 mm, and 0.824 mm, respectively. Each
vaccine lot underwent comprehensive quality control analyses to
ensure general safety, purity, identity, integrity, and uniform
water-in-oil droplet size. Stability of vaccines stored at 2–8C was
evaluated regularly using mouse immunogenicity tests and
physical and biochemical assays to verify the vaccine safety,
potency, uniformity, purity, and integrity until 4–10 months after
the termination of the human immunizations (Table 1).
The 160 mg/mL Pfs25/ISA 51 and 160 mg/mL Pvs25/ISA 51
vaccines were diluted with the PBS/ISA 51 (the adjuvant control
vaccine) to the final dose forms of 10 mg/mL or 40 mg/mL prior
to immunizations. As a result of different degrees of dilution, these
vaccines contained two different ratios of vaccine-containing vs.
vaccine-free water droplets, namely ratios of 1:15 and 1:3 for the
10 mg/mL and 40 mg/mL formulations, respectively. The test and
control vaccines were highly viscous and required vortexing prior
to and after manipulation to ensure homogeneity.
Intervention: Toxicology Study in Rabbits
To support the clinical use of the Pfs25/ISA 51 and Pvs25/ISA
51 vaccines, a toxicology study was conducted with New Zealand
White rabbits in compliance with Good Laboratory Practice
standards (GeneLogic, Gaithersburg, Maryland). Rabbits were
Pfs25 and Pvs25 Vaccine Trial
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responses to both vaccines, and they can be administered the full
dose intended for humans by the intramuscular route. A 14-week
study was performed using 84 rabbits in 4 groups. Groups 1, 2,
and 3 (24 rabbits in each group, 12 males and 12 females) were
each given 80 mg Pfs25/ISA 51 vaccine, 80 mg Pvs25/ISA 51
vaccine, or PBS/ISA 51 in a volume of 0.5 mL, respectively. The
preclinical vaccines were prepared following the same procedures
as for the clinical vaccines described above. The fourth group
containing 6 male and 6 female rabbits was given PBS alone as a
control. Although we planned to give human volunteers 2
vaccinations at a 4-month interval, the toxicology study design
was more aggressive: each rabbit received 4 immunizations at 1-
month intervals. Animals were observed during the course of the
study for morbidity, mortality, general health and signs of toxicity,
food consumption, body weight, clinical observations including
skin and fur characteristics, eye and mucous membrane,
respiratory, circulatory, autonomic and central nervous systems,
somatomotor and behavior patterns, ophthalmologic examination,
and dermal Draize observations. Hematology, blood chemistry,
and immunological analyses were performed on days 4, 32, 60, 88
and 99 (approximately 4 days post-each immunization). Major
tissues and organs were examined histologically on necropsy. Half
of groups 1, 2 and 3 were sacrificed 3 days after the fourth
immunization (day 88) for assessment of acute local reactogenicity.
The remaining half of the three groups was sacrificed 14 days after
the fourth immunization (day 99). The PBS control group was
sacrificed 14 days after the fourth immunization.
Intervention: Phase 1 Study Design
This was a partially blinded, dose escalating, controlled Phase 1
study in healthy US volunteers. The study was intended to enroll
10 volunteers in each of three dose levels (5, 20, and 80 mg per
dose in 0.5 mL) for both vaccine candidates, and a total of 12
controls for a total of 72 volunteers. Investigators were blinded as
to whether or not a volunteer received vaccine or the adjuvant
control, but were aware of the dose of vaccine to be administered.
Volunteers were randomly assigned to receive Pfs25/ISA 51,
Pvs25/ISA 51, or PBS/ISA 51, and were sequentially assigned to
higher dose groups as they were enrolled. Vaccinations were
staggered within each dose cohort such that 4 volunteers were
vaccinated a minimum of three weeks prior to the remaining 8
volunteers. A minimum interval of three weeks was required
between completion of vaccination of the first dose cohort and
start of vaccination of the next dose cohort. In addition, approval
by the Safety Monitoring Committee (SMC) was required prior to
escalation to a higher dose for each vaccine. Volunteers were
scheduled to receive two immunizations 4 months apart.
Vaccinations were given by IM injection in the deltoid muscle,
with the successive vaccination given in the alternate arm.
Objectives
The primary objective of this Phase 1 trial was to assess the
safety, reactogenicity, and immunogenicity of the transmission
blocking vaccine candidates Pfs25 and Pvs25, both adjuvanted
with Montanide ISA 51. Secondary objectives were to assess the
duration of specific antibody response over an 18 month period
and to assess the effect of a second booster dose on antibody levels.
Tertiary objectives were to measure the ability of vaccine-induced
antibody to inhibit oocyst development in a mosquito membrane
feeding assay, to determine the relationship between antibody
levels and degree of transmission blocking, and to establish human
standards for immune assays to be used for further development of
transmission blocking vaccines.
Outcomes: Safety and Tolerability
Safety and tolerability outcomes were the frequency of
immediate, systemic, and local adverse events, by severity and
relationship to vaccine. Following each vaccination, volunteers
were observed for 30 minutes for immediate adverse reactions.
The follow-up visits were scheduled for days 1, 3, 7, 14, and 21 for
evidence of local and systemic reactogenicity. Volunteers were
seen again at study days 30, 60, and 90 following vaccination for
evaluation of any acute complaints, local reactogenicity, and
assessment of immune status. Volunteers returned on study day
120 for a second vaccination and were followed on the same
schedule as described above, with the exception of the study day
90 visit. Volunteers were seen 5 months, 8 months and 12 months
following second vaccination for physical evaluation and immu-
nological assessment. Local adverse events included erythema,
induration, swelling, and tenderness at the site of injection.
Solicited systemic adverse events included fever (oral tempera-
ture$37.5uC), headache, nausea, malaise, myalgia, and arthralgia.
Volunteers recorded local and systemic events daily, as well as
Table 1. Results of Stability Studies Performed on Pfs25/ISA 51, Pvs25/ISA 51, and PBS/ISA 51.
Tests
a Sept. 2004 Mar. 2005 Sept. 2005 May 2006 Sept 2006
8 mo prior
b 2 mo prior
b 6 mo post
b 10 Mo post
b
Endotoxin Pass n.d. Pass n.d. Pass
Sterility Pass n.d. Pass n.d. Pass
Potency
c Pass Pass Pass Pass Pass
Color and Appearance Pass Pass Pass Pass Pass
Droplet Size Pass Pass Pass Pass Pass
Identity by SDS-PAGE and Western Blot
c Pass Pass Pass Pass Pass
Integrity by SDS-PAGE
c Pass Pass Pass Pass Pass
Protein Content
c Pass Pass Pass Pass Pass
aExcept for endotoxin and sterility tests, all other tests were performed in comparison with a freshly prepared vaccine as a reference. ‘‘Pass’’ indicated results obtained
from the stored vaccine were comparable to its reference.
bTime point relative to the vaccination period (May–October, 2005).
cThese tests are only applied to Pfs25/ISA 51 and Pvs25/ISA 51 vaccines.
doi:10.1371/journal.pone.0002636.t001
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days following each vaccination. An abbreviated history and
physical examination was performed at each follow-up visit. All
new or abnormal signs and symptoms were considered as adverse
events. Each adverse event was graded for severity and assigned
causality relative to the study vaccine. Severity was graded as
either absent/none (Grade 0), mild (Grade 1, easily tolerated),
moderate (Grade 2, interfered with activities of daily living), or
severe (Grade 3, prevented activities of daily living). Erythema,
induration, and swelling at the injection site were graded as
follows: 0=absent, 1=0–20 mm, 2=20–50 mm, 3=.50 mm.
Fever (oral) was graded as 0=,37.5uC, 1=37.5–38uC, 2=38–
39uC, and 3=.39uC. A complete blood count and white blood
cell differential, as well as serum creatinine and aspartate amino
transferase (AST) concentrations were performed immediately
prior to each vaccination and on days 3, 14, and 60 after each
vaccination. A complete blood count was also obtained on day 7
following vaccination. Serious adverse events (SAEs) were defined
as any adverse event resulting in death, life threatening, requiring
hospitalization, resulting in disability or incapacity or congenital
anomaly or birth defect, or any other event which required
intervention to prevent such outcomes.
Outcomes: Immunogenicity
Anti-Pfs25 and anti-Pvs25 IgG levels induced by the vaccines
were evaluated by a standard enzyme-linked immunosorbent assay
(ELISA) to measure serum antibodies to Pfs25 and Pvs25 proteins
[18]. Briefly, ELISA plates were coated with Pfs25 or Pvs25. Sera
collected from volunteers were tested against a set of serially
diluted reference standard serum. The anti-Pvs25 reference
standard serum was generated as described previously [19,20].
The anti-Pfs25 reference standard serum was generated from one
volunteer who developed significant antibody responses after the
second immunization. These reference standards were assigned
ELISA unit values equal to the reciprocal of the dilution giving an
OD405nm of 1. Absorbance of the set of serially diluted reference
standards was fitted to a 4-parameter hyperbolic function to
generate a standard curve. Using this standard curve, the
absorbance of an individual test serum was converted to an
antibody unit value.
Outcomes: Transmission Blocking Activity
Transmission blocking activity (TBA) of the sera was tested by
an ex vivo membrane feeding assay as described previously[21]
with following modifications: test sera were heat-inactivated and
diluted with a naı ¨ve human serum pool to a desired concentration.
Purified IgGs were buffer-exchanged and concentration-adjusted
with PBS prior to dilution with the naı ¨ve human serum pool. An in
vitro gametocyte culture of P. falciparum (NF54 line) was evaluated
for percentage of Stage V gametocytes (.0.5%) and the vitality of
exflagellation centers observed at 4006magnification. The culture
pellet was diluted with normal O+ RBC (Interstate Blood Bank,
Memphis, Tennessee) and normal heat-inactivated O+ human
serum pool (Interstate Blood Bank, Memphis, Tennessee) to
achieve 0.15%60.05% concentration of Stage V gametocytes and
haematocrit of 50%. This infected blood mixture was kept at
37uC, and aliquoted into 200 ml prior to the feed. One 200 ml-
aliquot of ‘‘infected blood’’ was mixed with 60 ml of the test serum
or antibodies, and immediately fed to 3–8 days old Anopheles
stephensi (Nijmegen strain) mosquitoes, starved for 24–30 hours,
through a membrane feeding apparatus using a thin stretched
parafilm membrane. Mosquitoes were kept for 7–8 days after the
feed at 26uC and high humidity conditions to allow parasites to
develop into oocysts. Infectivity was measured by dissecting at least
20 mosquitoes per sample, staining the midguts with 0.05%
mercurochrome solution in water for at least 20 min, and counting
the number of oocysts in each midgut. The feeding experiment
was not analyzed unless the average oocyst count in mosquitoes
fed with naı ¨ve human serum pool was more than four. Percent
inhibition of oocyst development per mosquito was determined by
the formula:
100 Mean Oocyst Nonegative control{Mean Oocyst Notest
 
Mean Oocyst Nonegative control
where the negative control feed used pre-vaccination sera from the
same volunteer. All samples or diluted samples were tested in
replica.
Sample size
A group size of 10 volunteers per dose was chosen based on the
distribution of antibody responses from previous clinical trials
[22,23], and would permit detection of at least a five-fold
difference in antibody concentration between dose groups using
a Mann-Whitney test, assuming a level of significance of 0.05 and
a power of 0.80. This sample size also gave 0.80 probability for
detecting one or more adverse events that occurred with a
probability of 0.15 per volunteer.
Randomization—Sequence generation and
Implementation
Volunteers in each cohort were randomly assigned to receive
vaccine or the adjuvant control. The study pharmacist determined
all treatment assignments by the use of a random number
generator prior to enrollment of any volunteers. Clinical staff
enrolled participants sequentially into each vaccine cohort.
Each cohort was enrolled separately for safety reasons, as stated
above.
Randomization—Allocation concealment
The treatment assignment log was kept in a locked file cabinet
to which only pharmacy staff had access. Each syringe was labeled
with the volunteer number and expiration time of the vaccine. The
syringe with the test article cohort was labeled in such a way that
the identity of the test article (vaccine or control) was not apparent.
Both vaccine and control were opaque white in appearance and
therefore indistinguishable.
Statistical methods
The study was terminated before completion of the scheduled
vaccinations. Due to the small numbers of subjects enrolled in the
study, statistical analysis regarding the frequency of adverse events
and antibody responses was not performed as planned.
The TBA is expressed as a percentage of inhibition of parasite
development in mosquitoes. Hill Plot [24] was used to model the
relationship between TBA and ELISA, as defined by formula:
Y~
100 X
b
 a
1z X
b
 a
where Y is the percent reduction of oocyst number, X is the ELISA
units in the test sample, a is the Hill coefficient, and b is ELISA
unit value that would result in 50% of reduction of the oocyst
number (IC50), using R (Version 2.6.0) [25]. The fit was weighted
by least squares with weights equal to the inverse of the variance,
which was estimated by the delta method [26].
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Participant Flow/Recruitment
Thirty-six volunteers were enrolled in the study from May
through October 2005. Participant recruitment and flow are shown
inFigure1.Thestudywasstopped priortocompletionofenrollment
due to unacceptable reactogenicity (see below). The mean age of the
volunteers at enrollment was 32.4 years (range 19–49), with no
significant difference in the ages of volunteers in each dose cohort
(data not shown). Forty-seven percent (47%) of volunteers identified
themselves as Caucasian; 39% as African American; six percent as
Hispanic; 6% as Asian; and 1 volunteer identified as ‘‘multi-racial’’.
Ten volunteers in each of the 5 mg Pvs25/ISA 51, 20 mg Pvs25/
ISA 51, and 5 mg Pfs25/ISA 51 dose groups were enrolled and
received their first vaccinations. In the 5 mg Pfs25/ISA 51 cohort,
5 of the volunteers received a second dose; 2 did not receive the
second vaccine because of a serious local reaction following the
first vaccination; 1 withdrew his consent prior to the second
vaccination; and 2 volunteers were ineligible for second vaccina-
tion (1 was out of the protocol-defined window for vaccination and
the other had a medical condition unrelated to the first vaccination
which excluded her from further vaccination). Six volunteers were
randomized to receive adjuvant control vaccine (PBS/ISA 51); 5
of those received one dose and 1 received two doses. Because
further vaccinations were stopped at this point due to unaccept-
able reactogenicity, as discussed below, volunteers in the other
dose cohorts did not receive a second vaccination. Volunteers who
received both doses of vaccine and the volunteers who developed
erythema nodosum (see below) were followed for a total of 18
months. Volunteers who received only one vaccination were
followed for a total duration of six months.
Outcomes and Estimation
Results of the Toxicology Study in Rabbits. Significant
specific antibody responses were induced by the repeated
immunizations of the test vaccines. No vaccine-related changes
were observed in mortality, clinical observations, body weights,
organ weights, food consumption, gross and clinical pathology,
ophthalmology, or gross necropsy observations. Minimal to mild
edema and/or erythema at the injection sites were observed in all
rabbit groups, including the group receiving PBS only, with
relatively similar incidence and severity. Histopathology showed
inflammation at the injection sites in all groups receiving
Montanide ISA 51 formulations, including Pfs25/ISA 51, Pvs25/
ISA 51, and PBS/ISA 51. The inflammation characteristics among
the groups varied slightly, and the presence of Pfs25 (the Pfs25/ISA
51 group) and Pvs25 (the Pvs25/ISA 51 group) did not significantly
alter this profile, indicating the inflammation was due to the
adjuvant Montanide ISA 51.
Safety and Tolerability Data of the Phase 1 Trial
Local adverse events.
In the groups receiving antigen with ISA 51, 6 volunteers
experienced severe local reaction, 4 experienced moderate local
reaction, and 14 experienced mild reaction (maximum severity for
each). Four of six volunteers who received the control vaccine
(PBS/ISA 51) complained of mild injection site pain lasting up to 4
days and two recipients reported mild erythema for one day. Local
adverse events are presented in Table 2. Injection site induration
began 13 to 21 days after vaccination and, in all but one volunteer,
resolved within eight weeks. Induration in this volunteer slowly
resolved over the course of approximately six months. The
induration observed in volunteers receiving 5 mg dose of Pfs25/
Figure 1. Participant Recruitment and Flow.
a One volunteer withdrew consent; one lost to follow up; study discontinued prior to second
vaccination of the 3 volunteers.
b One withdrew consent; two were withdrawn due to local reactions (severe swelling and induration in one volunteer
and severe swelling, induration, and pain in the other); two were ineligible due to previously undisclosed exclusion criteria (concurrent participation
in another investigational drug trial and mental illness).
c Two were withdrawn due to local reactions (severe swelling and induration in one volunteer
and severe swelling, induration, tenderness, and pain in the other).
d Two were withdrawn due to systemic adverse events (erythema nodosum).
doi:10.1371/journal.pone.0002636.g001
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either dose of Pvs25/ISA 51. With the exception of mild pain at
the injection site, the incidence of local adverse events did not
increase in volunteers who received a second dose of Pfs25/ISA 51
or in volunteers who received the higher 20 mg dose of Pvs25/ISA
51. One volunteer in the 20 mg Pvs25/ISA 51 group developed a
sterile abscess at the injection site, started on day 23 and lasted 19
days and drained spontaneously; this volunteer also had erythema
nodosum as described below.
Systemic and laboratory adverse events.
Related (possibly, probably, or definitely) solicited systemic
adverse events are shown in Table 3. Systemic adverse events
included mild to severe arthralgia, headache, malaise, myalgia,
and nausea. Following first vaccination with 5 mg Pfs25/ISA 51,
mild arthralgia and headache lasting 1–2 days were reported by
one volunteer. Following second vaccination, one subject reported
headache, malaise, and nausea for 1–2 days. One volunteer had
Grade 1 leukopenia on two instances: 57 days following first
vaccination and 14 days following second vaccination. The first
episode of leukopenia resolved after ninety days and the second
episode resolved within 7 days of onset; only the second was
judged to be possibly related to vaccination. This subject also
developed mild ketonuria thought to be possibly related to
vaccination. One volunteer developed a severe leukemoid
reaction, described below.
Systemic adverse events after one dose of 5 mg Pvs25/ISA 51
included mild headache in one volunteer. Three volunteers
developed grade 1 leukopenia, however the onset of leukopenia
was greater than 120 days after first vaccination in two of the three
volunteers and these were judged to be unlikely to be related to
vaccination. Systemic events after one dose of 20 mg Pvs25/ISA 51
included two cases of erythema nodosum with associated headache,
arthralgia, and myalgia, and a leukemoid reaction (described below).
Leukemoid reactions.
Two volunteers developed leukemoid reactions during the course
of this study. One volunteer in the 5 mg Pfs25/ISA 51 group
developed a leukemoid reaction 14 days after receiving his second
dose of vaccine, with a total white blood cell (WBC) count of 35,700
cells/ml, and an absolute neutrophil count 27,489 cells/mL with 2%
bands (left shift). The volunteer was clinically well, and reported that
he had donated blood one day before at his workplace requiring
three attempts at phlebotomy. The CBC was repeated one day later
and WBC count was 14,500/mL. Blood cultures were also obtained
and were negative; C-reactive protein (CRP) level and erythrocyte
sedimentation rate were normal. The WBC count returned to
baseline within one week and remained within normal limits. The
volunteer remained otherwise well for the duration of the study. The
leukemoid reaction was graded as possibly related to vaccination.
One volunteer in the 20 mg Pvs25/ISA 51 group was seen for
regularly scheduled study follow up 120 days after receiving
vaccination. She was clinically well at that time but her WBC count
was 34,600 cells/mL with a left shift. The volunteer did not return to
the clinic for repeat lab testing and evaluation until four weeks later,
despite numerous requests. Her WBC count was repeated at that
time and was normal. It remained normal on subsequent visits. This
reaction was also graded as possibly related to vaccination.
Table 2. Number of volunteers in each vaccination group experiencing the indicated solicited local adverse event.
Vaccination Group N
a Pain Grade Tenderness Grade Induration Grade
b Swelling Grade
b Erythema Grade
c
1231231231231
5 mg Pfs25/ISA51 Dose 1 1 0 2211000021133
5 mg Pfs25/ISA51 Dose 2 54002000000101
5 mg Pvs25/ISA51 Dose 1 1 0 5113210220020
20 mg Pvs25/ISA51 Dose 1 1 0 6202100011102
PBS/ISA51 64001000000002
aNumber of volunteers in the vaccination group.
bGrade 1=0–20 mm, Grade 2=20–50 mm, Grade 3=.50 mm.
cAll erythema was Grade 1.
doi:10.1371/journal.pone.0002636.t002
Table 3. Number of volunteers in each vaccination group experiencing the indicated solicited adverse event (possibly, probably,
or definitely related to vaccination).
Vaccination Group N
a Headache Grade Arthralgia Grade Myalgia Grade Malaise Grade Nausea Grade
b Leukopenia Grade
b
1 23123 1231231 1
5 mg Pfs25/ISA51 Dose 1 1 0 1 00100 0000000 0
5 mg Pfs25/ISA51 Dose 2 51 00000 0000101 1
5 mg Pvs25/ISA51 Dose 1 1 0 1 00000 0000000 1
20 mg Pvs25/ISA51 Dose 1 1 0 0 01011 0110011 0
PBS/ISA51 61 00000 0002001 1
aNumber of volunteers in the vaccination group.
bAll nausea and leukopenia were Grade 1.
doi:10.1371/journal.pone.0002636.t003
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Two volunteers who received one dose of 20 mg Pvs25/ISA 51
developed erythema nodosum, both at 18 days after vaccination.
One volunteer was a 25 year-old Asian female; the other was a 26
year old Caucasian female; both were taking oral contraceptives.
Symptoms in the 25 year old were graded as moderate and
included painful nodules on the lower legs, and erythematous
macules on the arms and legs. The other volunteer had symptoms
graded as severe with fever, headache, arthralgia, and conjunc-
tivitis in addition to painful nodules on her anterior lower legs. A
transient elevation of CRP occurred in both volunteers: a CRP
level of 75 mg/L (upper limit of normal is , 8 mg/L) was seen in
the volunteer with the severe reaction while the other volunteer
had only a mild elevation of CRP with a value of 8 mg/L. An
elevated level of complement (CH50) was also found in the
volunteer with the moderate reaction. A dermatology consult was
obtained and erythema nodosum-like syndrome was diagnosed in
both volunteers, with skin biopsy results for the patient with the
severe reaction showing non-specific panniculitis consistent with
erythema nodosum. The other volunteer did not undergo a skin
biopsy. The severe reaction resolved at 38 days, and the moderate
reaction resolved at 12 days. Both were graded as probably related
to vaccination.
This study was closed to enrollment and vaccinations were
stopped due to the erythema nodosum reactions.
Immunogenicity Data. Pvs25/ISA 51 group: Sixteen of the
20 volunteers, including one with a leukemoid reaction and one of
the two with grade 3 induration, failed to develop detectable
antibodies against Pvs25 (i.e. antibody levels were lower than 25
ELISA units, the background level) at any time during the follow-
up period. The other volunteer with grade 3 induration developed
measurable antibodies with a peak level of 96 units on day 120.
Antibodies were first detectable at day 60, about 3 weeks following
resolution of the induration. Both volunteers with erythema
nodosum had detectable antibody levels starting at day 30. The
volunteer with a severe reaction had a peak antibody level of 219
ELISA units on day 60, whereas the volunteer with a moderate
reaction had a peak level of 583 units on day 150. The fourth
volunteer developed antibody levels of 34 units on day 60 and 84
units on day 120, and had no significant adverse reactions.
Pfs25/ISA 51 group: The antibody responses against Pfs25 are
detailed in Table 4. Four of 10 volunteers, including the one that
developed a leukemoid reaction (Volunteer ‘‘C’’), had no
detectable antibodies against Pfs25 (i.e. ,25 ELISA units) by
day 120 following the first vaccination. Of the 2 volunteers that
developed grade 3 induration, one (Volunteer ‘‘H’’) had a minimal
antibody level of 30 ELISA units on day 90, 30 days after the
induration resolved. The other (Volunteer ‘‘G’’) had 132 ELISA
units on day 60. The antibody levels declined over time, along
with the induration which resolved by Day 370. These 2
volunteers did not receive the second vaccination.
All 5 volunteers (Volunteers ‘‘A’’ through ‘‘E’’) receiving a second
dose of 5 mg Pfs25/ISA 51 developed substantial antibody levels
against Pfs25 following the second vaccination (Table 4). The
antibody levels reached a peak 30–60 days after the second
vaccination and the geometric mean of the peak of this group was
1295 ELISAunits.The antibody slowly decayed, but all5 volunteers
maintained detectable antibody levels 1 year after vaccination.
Transmission Blocking Activity of the Antisera. Antisera
from 4 of the 5 volunteers who completed 2 scheduled doses of 5 mg
Pfs25/ISA51 were testedfortheirabilityto blocktransmission.Inex
vivo membrane feeding assays, one antiserum that contained 7322
ELISA units resulted in reduction of the parasite in mosquitoes by
.90%. The transmission blocking activity decreased when the
serum was diluted in the assay. Three antisera had low to moderate
antibody titers of 630 to 1520 ELISA units. These sera gave low to
moderatetransmissionblockingactivity(18–47%reductioninoocyst
number). Figure 2 shows the relationship between antibody titer and
transmission blocking activity in the sera. From the correlation
between antibody and blocking, 1093 units (95% Confidence
Interval, 683–1565 units) of antibody are required to reach a 50%
reduction in oocyst density.
Discussion
Interpretation
This study involved the first in-human use of two novel antigen/
adjuvant combinations. A previous clinical trial of one of these
antigens, the same Pvs25 used in this study but adsorbed to
AlhydrogelH, showed minimal reactogenicity, with injection site
tenderness as the most commonly observed adverse event.
Table 4. Anti-Pfs25 Antibody Levels Following Vaccination of 5 mg Pfs25/ISA 51
a.
Volunteer Anti-Pfs25 ELISA Units on Study Days
c
0 14 30 60 90 120 134 150 180 270 360 556
A ,25 ,25 ,25 ,25 ,25 ,25 932 1527 672 167 95 52
B ,25 ,25 ,25 ,25 ,25 ,25 263 631 362 116 64 40
C ,25 ,25 ,25 30 28 29 469 694 514 168 59 34
D ,25 ,25 ,25 ,25 ,25 36 1688 6329 7322 3657 1653 1022
E ,25 ,25 ,25 ,25 ,25 ,25 347 665 745 204 108 n.d.
F
b ,25 ,25 ,25 ,25 ,25 n.d. n.d. n.d. ,25 n.d. n.d. n.d.
G
b ,25 ,25 ,25 132 123 100 n.d. 98 87 53 39 n.d.
H
b ,25 ,25 ,25 ,25 30 41 n.d. 37 39 36 n.d. n.d.
I
b ,25 ,25 ,25 ,25 ,25 ,25 n.d. n.d. ,25 n.d. n.d. n.d.
J
b ,25 ,25 ,25 ,25 n.d. ,25 ,25 n.d. ,25 n.d. n.d. n.d.
aThe volunteers were scheduled to receive 2 vaccinations on days 0 and 120.
bThese volunteers did not receive the second vaccination.
c,25, below the assay detection limit; n.d., not tested because samples were not available.
doi:10.1371/journal.pone.0002636.t004
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[27]. Two previous human trials with a similar recombinant Pfs25
antigen, one in which the antigen was adsorbed to AlhydrogelH
and one where a prime/boost strategy was used, also showed an
adverse event pattern limited to local reactogenicity, although one
volunteer had an atypical contralateral hypersensitivity reaction
thought to be due to free antigen dissociated from the alum [4,28].
Due to Pfs25’s poor immunogenicity and inadequate binding to
Alhydrogel, a different adjuvant platform using Montanide ISA 51
was explored for its further clinical development
Montanide ISA 51 has been used as an adjuvant with
investigational agents in a large number of clinical trials, with
the most common adverse reactions being local injection site pain
or swelling, although some studies have reported injection site
nodules and sterile abscesses, [29–31]. Other water-in-oil
formulations (e.g. FIAt and Montanide ISA 720) have also
occasionally caused moderate to severe local reactions, including
sterile abscesses. This class of adjuvant has thus far been free of
reports of severe vaccine associated-systemic reactogenicity. Since
the frequency of the local reactions varies greatly according to
antigen and dose, it is difficult to predict if a new antigen will give
rise to an unacceptable frequency of reactogenicity. In some
situations, a relatively high incidence of moderate or severe local
injection site reactions may be an acceptable safety risk in a
vaccine with a high benefit potential, such as with malaria vaccines
[32]. Therefore it was considered acceptable to proceed with a
Phase 1 study with staggered vaccinations, designed to allow safety
assessment prior to the next dose cohort and minimize the number
of severe adverse events.
Despite the lack of issues identified in preclinical studies
including a toxicology study conducted in rabbits, both Pfs25/
ISA 51 and Pvs25/ISA 51 proved to be quite reactogenic in
humans. Two types of local reactogenicity were observed: local
tenderness and swelling occurring within a few days of vaccination,
and induration that occurred approximately 2 weeks after
vaccination. In this study development of induration did not seem
to be associated with higher antibody response whereas in previous
studies, indurations tended to be associated with the subjects with
the highest antibody responses [33].
Although indurations and other local reactogenicity were of
concern, these were not regarded as severe enough to stop the
trial. The trigger to cease vaccination was development of
erythema nodosum like symptoms in 2 of 10 volunteers who
received 20 mg Pvs25/ISA 51. Erythema nodosum is an
inflammatory panniculitis, commonly associated with underlying
systemic disease or infections such as sarcoidosis or tuberculosis. It
is more common in women and is also associated with the use of
oral contraceptives [34]. Erythema nodosum has been reported in
association with both plasma derived and recombinant hepatitis B
vaccines, and with typhoid vaccination [35–39]. Given the parallel
timing and presentations of these two reactions, the likelihood of a
causal relationship to vaccination is high. The two leukemoid
reactions were less similar in that they occurred in volunteers who
received different vaccines, and one occurred 14 days after
vaccination and one occurred 120 days after vaccination.
However, given the absence of any other plausible explanation
for these events a causal relationship is possible, and perhaps likely
for the reaction which occurred 14 days after vaccination.
Itisunlikely that observed systemic adverseevents were associated
with the antigenalone. Three cases ofsystemicreactions (2erythema
nodosum cases and 1 transient leukemoid case) occurred in cohorts
receiving Pvs25/ISA 51 vaccine. The same production lot of Pvs25
was used to produce the Pvs25/Alhydrogel vaccine that was well
tolerated in humans [40]. Both stored Pfs25/ISA 51 and Pvs25/ISA
51 vaccines met specified criteria in routine stability and potency
studies (Table 1). Combining the evidence from the literature and
our observations in this trial, it seems likely that the erythema
nodosum reactions and possibly the transient leukemoid reactions
were related to the specific antigen/adjuvant combinations. These
reactions were not predicted by the toxicity study conducted in
rabbits, nor have they been seen in other trials in mice, Aotus
monkeys and rhesus monkeys.
Although the trial was stopped due to adverse events, the data
from volunteers receiving 2 doses of 5 mg Pfs25/ISA 51 clearly show
that it is possible to induce antibody in humans that can effectively
block parasite development in mosquitoes. The data also enabled an
estimate of antibody levels (1093 with 95% CI 683–1565 ELISA
units) required to give 50% blockage of oocyst development. Using
this figure and results from recent modeling of the impact of
mosquito stage transmission blocking vaccines [41], the average
antibody levels (geometric mean of 1295 units) in this dose group
wouldcorrespond toa1.5folddecreaseininoculationratesif90%of
the gametocyte carriers in a village were vaccinated, even though
5 mg was the lowest dose group in the study.
Generalization
In addition to local reactogenicity, this study observed for the
first time an association between systemic adverse events and a
specific antigen-Montanide ISA 51 formulation. These results
highlight the need for careful trial design in Phase 1 studies with
novel antigen/adjuvant combinations [42]. The induction of
transmission blocking antibodies in volunteers who received the
lowest scheduled doses of Pfs25/ISA 51 demonstrates the
feasibility of this approach. However, the severity and duration
of the local reactions seen in this study, combined with the
observed systemic reactions, make further progression of the
Montanide ISA 51 formulations unlikely. Current efforts are
focused on the development of a well tolerated formulation
capable of inducing strong immune responses.
Figure 2. Correlation of anti-Pfs25H antibody units with
transmission blocking activity measured as percent reduction
in oocysts per mosquito. Sera or purified IgGs were tested in replica in
variousdilution.Thenon-linearequation:Y~
100 X
b
 a
1z X
b
 a wasusedtofitthe
data, where variables Y and X arethe percent reductionofoocystnumber,
and the ELISA units, respectively, the curve parameters were calculated as
a =1.27 (95% CI 0.96–1.68) and b=1093 (95% CI 682–1565).
doi:10.1371/journal.pone.0002636.g002
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